Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New program aims to cut unnecessary pills for dementia patients

NCT ID NCT04938648

First seen Jun 22, 2026 · Last updated Jun 22, 2026

Summary

This study tested a program where a pharmacist worked with people living with dementia, their care partners, and their doctors to review and reduce unnecessary medications. The goal was to simplify medication routines and lower treatment burden. The study included 138 participants aged 65 and older with dementia and multiple chronic conditions.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALZHEIMER DISEASE AND RELATED DEMENTIAS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Johns Hopkins Bayview Medical Center

    Baltimore, Maryland, 21224, United States

  • Kaiser Permanente

    Aurora, Colorado, 80014, United States

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Pharmacist-led deprescribing intervention (educational materials, telehealth visit, and provider communication)

What this could lead to

If successful, this approach could help people with dementia take fewer unnecessary medications, reducing side effects and simplifying daily care.

What could go wrong

This is a small feasibility study, not a large trial. The program may not work for everyone, and deprescribing must be done carefully to avoid withdrawal risks.

Conditions

The condition(s) this trial relates to.

Alzheimer Disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.